Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Age and its association with low insulin and high amyloid-β peptides in blood.

Li H, Zhu H, Wallack M, Mwamburi M, Abdul-Hay SO, Leissring MA, Qiu WQ.

J Alzheimers Dis. 2016;49(1):129-37. doi: 10.3233/JAD-150428.

2.

Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors.

Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, Hodder P, Leissring MA.

ACS Chem Biol. 2015 Dec 18;10(12):2716-24. doi: 10.1021/acschembio.5b00334. Epub 2015 Sep 30.

PMID:
26398879
3.

ML345, A Small-Molecule Inhibitor of the Insulin-Degrading Enzyme (IDE).

Bannister TD, Wang H, Abdul-Hay SO, Masson A, Madoux F, Ferguson J, Mercer BA, Schurer S, Zuhl A, Cravatt BF, Leissring MA, Hodder P.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2014 May 13].

4.

The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme.

Kurklinsky S, Abdul-Hay SO, McGuire MP, Howard EA, Knight J, Leissring MA.

Horm Metab Res. 2014 Jan;46(1):73-4. doi: 10.1055/s-0033-1353211. Epub 2013 Aug 23. No abstract available.

PMID:
23975847
5.

LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD).

Lincoln S, Allen M, Cox CL, Walker LP, Malphrus K, Qiu Y, Nguyen T, Rowley C, Kouri N, Crook J, Pankratz VS, Younkin S, Younkin L, Carrasquillo M, Zou F, Abdul-Hay SO, Springer W, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Lewis JM, Dickson D, Graff-Radford NR, Petersen RC, Eckman E, Younkin SG, Ertekin-Taner N.

PLoS One. 2013 Jun 4;8(6):e64164. doi: 10.1371/journal.pone.0064164. Print 2013.

6.

Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.

Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA.

J Med Chem. 2013 Mar 28;56(6):2246-55. doi: 10.1021/jm301280p. Epub 2013 Mar 15.

PMID:
23437776
7.

Identification of BACE2 as an avid ß-amyloid-degrading protease.

Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA.

Mol Neurodegener. 2012 Sep 17;7:46. doi: 10.1186/1750-1326-7-46.

8.

Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?

Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ.

J Alzheimers Dis. 2012;29(2):329-40. doi: 10.3233/JAD-2011-111472.

9.

Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance.

Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA.

PLoS One. 2011;6(6):e20818. doi: 10.1371/journal.pone.0020818. Epub 2011 Jun 9.

10.

Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.

Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang WJ, Stein RL, Cuny GD, Selkoe DJ.

PLoS One. 2010 May 7;5(5):e10504. doi: 10.1371/journal.pone.0010504.

11.

Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.

Abdul-Hay SO, Edirisinghe P, Thatcher GR.

J Neurochem. 2009 Nov;111(3):683-95. doi: 10.1111/j.1471-4159.2009.06355.x. Epub 2009 Aug 22.

12.

NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.

Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR.

J Neurochem. 2009 Nov;111(3):766-76. doi: 10.1111/j.1471-4159.2009.06353.x. Epub 2009 Aug 21.

13.

Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors.

Chirapu SR, Pachaiyappan B, Nural HF, Cheng X, Yuan H, Lankin DC, Abdul-Hay SO, Thatcher GR, Shen Y, Kozikowski AP, Petukhov PA.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):264-74. doi: 10.1016/j.bmcl.2008.10.096. Epub 2008 Oct 25.

14.

Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention.

Hagos GK, Abdul-Hay SO, Sohn J, Edirisinghe PD, Chandrasena RE, Wang Z, Li Q, Thatcher GR.

Mol Pharmacol. 2008 Nov;74(5):1381-91. doi: 10.1124/mol.108.046664. Epub 2008 Aug 1.

PMID:
18676677
15.

Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality.

Dunlap T, Abdul-Hay SO, Chandrasena RE, Hagos GK, Sinha V, Wang Z, Wang H, Thatcher GR.

Nitric Oxide. 2008 Sep;19(2):115-24. doi: 10.1016/j.niox.2008.04.013. Epub 2008 Apr 23.

Supplemental Content

Loading ...
Support Center